Update on HIV-associated neurocognitive disorders topical collection on infection

Current Neurology and Neuroscience Reports

Volumn 13, Issue 10, 2013, Pages

  Alfahad, Tariq B ^a   Nath, Avindra ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Antiretroviral; Compartmentalization; HIV associated neurocognitive disorders; Human immunodeficiency virus; Latency

Indexed keywords

COGNITION DISORDERS; COMPLICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NERVOUS SYSTEM DISEASES; NOMENCLATURE; RISK FACTOR; VIROLOGY;

COGNITION DISORDERS; HIV INFECTIONS; HUMANS; NERVOUS SYSTEM DISEASES; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 84895931616     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0387-7     Document Type: Article

References (66)

1. Tanne JH. Nearly 40 million people worldwide are infected with HIV. BMJ. 2006;332:1289.
2. Hogan C, Wilkins E. Neurological complications in HIV. Clin Med. 2011;11(6):571-5.
3. •• Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16. This study shows in a large multicenter cohort that the prevalence of HAND is still substantial despite adequate ART.
4. Carey CL, Woods SP, Rippeth JD, et al. Prospective memory in HIV-1 infection. J Clin Exp Neuropsychol. 2006;28(4):536-48.
5. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944-50. (Pubitemid 36076569)
6. Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology. 2002;59:1563-7. (Pubitemid 35387063)
7. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-99. (Pubitemid 350059308)
8. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8(1):33-44. (Pubitemid 46011997)
9. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543-55. (Pubitemid 41139976)
10. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3-16.
11. • Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011;24(3):284-90. This review discusses the clinical manifestations, pathophysiology, and management of IRIS affecting the CNS in HIV-infected individuals.
12. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002;99:13795. (Pubitemid 35215460)
13. Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157:197-202. (Pubitemid 39576655)
14. Singh KK, Ellis RJ, Marquie-Beck J, et al. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol. 2004;157:185-92. (Pubitemid 39576653)
15. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014-28.
16. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78:485-92.
17. Valcour VG, Sacktor NC, Paul RH, et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging with HIV Cohort. J Acquir Immune Defic Syndr. 2006;43:405-10. (Pubitemid 44737096)
18. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS cohort study. Neurology. 1993;43:2245-52. (Pubitemid 23346956)
19. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292-9.
20. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry. 1998;65:29-33. (Pubitemid 28302353)
21. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS. 2005;19:127-35. (Pubitemid 40409531)
22. • Achim CL, Adame A, Dumaop W, et al. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol. 2009;4:190-9. This demonstrates that the amyloid based pathology in HIV infected individuals is distinctly different from that in Alzheimer's disease.
23. Cherner M, Ellis RJ, Lazzaretto D, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS. 2004;18 Suppl 1:S27-34.
24. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004;63:822-7. (Pubitemid 39297641)
25. Sacktor N, Skolasky R, Selnes OA, et al. Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals. J Neurovirol. 2007;13:203-9. (Pubitemid 47050646)
26. Parsons TD, Tucker KA, Hall CD, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS. 2006;20:1591-5. (Pubitemid 44162400)
27. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265-73. (Pubitemid 41122414)
28. Sun B, Abadjian L, Rempel H, et al. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr. 2013;62:190-6.
29. •• Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS. 2011;25(5):577-80. This article discusses the challenges in the eradication of HIV from the brain.
30. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879-84. (Pubitemid 351723493)
31. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3:e46. (Pubitemid 46683483)
32. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002;186 Suppl 2:S193-8. (Pubitemid 35370481)
33. Johnson TP, Patel K, Johnson KR, et al. Induction of IL-17 and non-classical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci USA. 2013. doi: 10.1073/pnas.1308673110.
34. Bruce-Keller AJ, Chauhan A, Dimayuga FO, et al. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci. 2003;23(23):8417-22. (Pubitemid 37129659)
35. Wang T, Lee MH, Choi E, et al. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1. 3 channel. PLoS One. 2012;7(8):e43950.
36. Wang T, Allie R, Conant K, et al. Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J. 2006;20(8):1209-11. (Pubitemid 44943874)
37. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3(6):e2516.
38. Kamat A, Ancuta P, Blumberg RS, et al. Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation. PLoS One. 2010;5(11):e15533.
39. Dohgu S, Fleegal-DeMotta MA, Banks WA. Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by luminal microvessel IL-6 and GM-CSF. J Neuroinflammation. 2011;8(1):167.
40. Pang S, Koyanagi Y, Miles S, et al. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature. 1990;343(6253):85-9. (Pubitemid 20036361)
41. Wu Y, Marsh JW. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science. 2001;293(5534):1503-6. (Pubitemid 32801554)
42. Teo I, Veryard C, Barnes H, et al. Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol. 1997;71(4):2928-33. (Pubitemid 27119935)
43. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23(11):1359-66.
44. Gray LR, Gabuzda D, Cowley D, et al. CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates. J Neurovirol. 2011;17(1):82-91.
45. Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A. 2006;103(41):15160-5. (Pubitemid 44583181)
46. Gonzalez-Perez MP, O'Connell O, Lin R, et al. Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue. Retrovirology. 2012;9:20.
47. Cowley D, Gray LR, Wesselingh SL, et al. Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. J Neurovirol. 2011;17(1):70-81.
48. Li W, Huang Y, Reid R, et al. NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci. 2008;28(47):12190-8.
49. Olivieri KC, Agopian KA, Mukerji J, et al. Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retrovir. 2010;26(4):495-500.
50. Thompson KA, Churchill MJ, Gorry PR, et al. Astrocyte specific viral strains in HIV dementia. Ann Neurol. 2004;56(6):873-7. (Pubitemid 39578452)
51. Lamers SL, Gray RR, Salemi M, et al. HIV-1 phylogenetic analysis shows HIV-1 transits through the meninges to brain and peripheral tissues. Infect Genet Evol. 2011;11(1):31-7.
52. Vissers M, Stelma FF, Koopmans PP. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system? J Clin Virol. 2010;49(4):231-8.
53. Lamers SL, Salemi M, Galligan DC, et al. Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol. 2010;16(3):230-41.
54. Aquaro S, Calio R, Balzarini J, et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 2002;55(2):209-25. (Pubitemid 34718126)
55. Cinque P, Presi S, Bestetti A, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retrovir. 2001;17(5):377-83. (Pubitemid 32506929)
56. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45-55.
57. • Cohen J. Understanding HIV latency to undo it. Science. 2011;332(6031):786. This reviews all the ongoing clinical trials for eradication of HIV infection.
58. Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011;24(3):284-90.
59. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28(8):839-47.
60. Ene L, Duiculescu D, Ruta SM. How much do antiretroviral drugs penetrate into the central nervous system? J Med Life. 2011;4(4):432.
61. Sawchuk RJ, Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev. 1999;39(1):5-31. (Pubitemid 29430227)
62. Croteau D, Letendre S, Best BM, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010;54(12):5156-60.
63. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204(12):1936-45.
64. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine. 2009;4(5):557-74.
65. Rao KS, Reddy MK, Horning JL. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29(33):4429-38.
66. Tan IL, McArthur JC. HIV-Associated neurological disorders. CNS Drugs. 2012;26(2):123-34.